|
Commitments and Contingencies - Additional Information (Detail) (USD $)
|
0 Months Ended | 3 Months Ended | 0 Months Ended | 1 Months Ended | 3 Months Ended | 3 Months Ended | 3 Months Ended | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Oct. 16, 2012
|
Aug. 31, 2014
|
Aug. 31, 2014
Progenics Pharmaceuticals, Inc
|
Jan. 20, 2014
Project Work Order
Project
|
Dec. 31, 2013
Project Work Order
|
Aug. 31, 2014
Project Work Order
|
Aug. 31, 2014
Project Work Order
One Study
|
Aug. 31, 2014
Project Work Order
Amarex Clinical Research, LLC
|
Aug. 31, 2014
Milestone Payments
US Phase III trial
|
Aug. 31, 2014
Milestone Payments
US new drug application approval by the FDA
|
Aug. 31, 2014
Development Milestone Payments
|
Aug. 31, 2014
Development Milestone Payments
US Phase III trial
|
Aug. 31, 2014
Development Milestone Payments
US new drug application approval by the FDA
|
Aug. 31, 2014
Development Milestone Payments
New Drug Application with the FDA
|
Aug. 31, 2014
Director
|
Aug. 31, 2014
Director
Stock Option Award Agreement dated Dec 6,2010
|
Aug. 31, 2014
Director
Stock Option Award Agreement dated September 22,2010
|
Aug. 31, 2014
Director
Stock Option Award Agreement dated April 16,2012
|
|
| Commitment And Contingencies [Line Items] | ||||||||||||||||||
| Salary | $ 13,890 | |||||||||||||||||
| Cash severance payment | 13,890 | |||||||||||||||||
| Severance period | 33 months | |||||||||||||||||
| Reimbursement of health insurance period | 9 months | |||||||||||||||||
| Stock option award agreement | 500,000 | 750,000 | ||||||||||||||||
| Stock Option granted, per share | $ 1.19 | $ 2.00 | ||||||||||||||||
| Options granted | 25,000 | |||||||||||||||||
| Option immediate vesting | 1,500,000 | |||||||||||||||||
| Options forfeiture | 750,000 | |||||||||||||||||
| Severance expense | 42,000 | |||||||||||||||||
| Severance liabilities | 153,000 | |||||||||||||||||
| Asset purchase, cash paid | 3,500,000 | 1,500,000 | 5,000,000 | 1,000,000 | 500,000 | 500,000 | ||||||||||||
| Royalty on every net sales | 5.00% | 7.50% | ||||||||||||||||
| Asset Purchase Agreement Aggregate Consideration Paying Period | 10 years | 10 years | ||||||||||||||||
| Minimum annual license maintenance fees | 150,000 | |||||||||||||||||
| Number of research studies projects | 2 | |||||||||||||||||
| Number of projects terminated | 1 | |||||||||||||||||
| Project termination notice period | 30 days | |||||||||||||||||
| Estimated combined cost of two separate studies | 9,300,000 | |||||||||||||||||
| Estimated cost terminated without penalty | 4,300,000 | |||||||||||||||||
| Estimated remaining cost | 3,700,000 | 1,000,000 | ||||||||||||||||
| Payment to CRO for deposit | 790,000 | |||||||||||||||||
| Termination period upon prior notice | 30 days | |||||||||||||||||
| Percentage of remaining contract amount for direct services to be paid upon termination | 30.00% | |||||||||||||||||
| Postponed research studies amounts allowed to be applied to all amounts due to the CRO | $ 343,000 | |||||||||||||||||